Investors

News

Date Title  
Toggle Summary Forward Pharma to Participate in the Fall Investor Summit in New York
COPENHAGEN, Denmark , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (the “Company”) today announced that Chief Executive Officer, Dr. Claus Bo Svendsen, will participate in the Fall Investor Summit investor conference ( https://www.microcapconf.com ) in New York, NY . Dr.
Toggle Summary Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange
COPENHAGEN, Denmark, June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market.
Toggle Summary Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange
COPENHAGEN, Denmark , June 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market .
Toggle Summary Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018
COPENHAGEN, Denmark , April 04, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018 .
Toggle Summary Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference
COPENHAGEN, Denmark , March 27, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY . Dr.
Toggle Summary Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference
COPENHAGEN, Denmark , March 27, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY . Dr.
Toggle Summary Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference
The U.S. Court of Appeals for the Federal Circuit has affirmed the decision of the Patent Trial and Appeal Board in the U.S. patent interference proceeding The appeal of the European EP2801355 patent opposition continues Forward expects to reduce operating expenses to match the current situation
Toggle Summary Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcare Conference
COPENHAGEN, Denmark , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY . Dr.
Toggle Summary Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018
COPENHAGEN, Denmark , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We”, “Forward” or the “Company” and together with its subsidiaries, the “Group”), today reported consolidated financial results for the six-month period ended June 30, 2018 .
Toggle Summary Forward Pharma to Participate in the LSX Nordic Congress
COPENHAGEN, Denmark , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will participate in the LSX Nordic Congress being held August 29-30, 2018 in Stockholm, Sweden . Dr.
Toggle Summary Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent
COPENHAGEN, Denmark , May 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355
Toggle Summary Forward Pharma Reports Full-Year 2017 Financial and Operational Results
COPENHAGEN, Denmark , April 30, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the year ended December 31, 2017 . Net income for the year ended December 31, 2017 was $917.1 million , or $2.30 per diluted share,
Toggle Summary Forward Pharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
COPENHAGEN, Denmark , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will give a corporate update at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY .
Toggle Summary Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent
Forward Pharma Expects to Appeal the Decision Upon Review COPENHAGEN, Denmark , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that the European Patent Office (the “EPO”) has revoked the EP2801355 patent (the “’355 patent”) following
Toggle Summary Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit
Oral argument expected in second or third quarter of 2018 COPENHAGEN, Denmark , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”)
Toggle Summary Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018
COPENHAGEN, Denmark , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of further written submissions in the European Opposition Proceeding for the EP2801355 patent (“the ‘355 patent”) with the Opposition Division of the
Toggle Summary Forward Pharma to Participate in Investor Conferences in December
COPENHAGEN, Denmark , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will participate in two upcoming investor conferences in New York, NY . Dr.
Toggle Summary Forward Pharma Announces Completion of Corporate Restructuring Plan
COPENHAGEN, Denmark , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (“Forward Pharma”) today announced the completion of its previously announced corporate restructuring plan (the “Restructuring”) substantially in the form set forth in Appendix D to the Settlement and License
Toggle Summary Forward Pharma to Participate in the Nordic-American Life Science Conference
COPENHAGEN, Denmark , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will participate in the Nordic-American Life Science Conference being held November 13-14, 2017 in New York, NY
Toggle Summary Forward Pharma Reports Financial and Operational Results from the First Six Months of 2017
COPENHAGEN, Denmark , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the six-month period ended June 30, 2017 .  Net income for the six-month period ended June 30, 2017 was $941.2 million , or $1.91 per
Toggle Summary Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) of the opening brief for the appeal of the PTAB decision that ended the
Toggle Summary Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders
COPENHAGEN, Denmark , Sept. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (“the Company” or “Forward”) today announced the final approval by the Company’s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a capital reduction (the
Toggle Summary Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting
COPENHAGEN, Denmark , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (“the Company” or “Forward”) today announced the result of the extraordinary general meeting of its shareholders held on August 2, 2017 (the “Extraordinary General Meeting”), where the requisite majority of the
Toggle Summary Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders
COPENHAGEN, Denmark , July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S  (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction.
Toggle Summary Forward Pharma CEO to Present at the JMP Securities 2017 Life Sciences Conference on June 20, 2017
COPENHAGEN, Denmark , June 14, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will present at the JMP Securities 2017 Life Sciences Conference being held June 20-21, 2017 in New York, NY .
Toggle Summary Forward Pharma CEO to Present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017
COPENHAGEN, Denmark , June 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference being held June 6-9, 2017 in New York, NY . Dr.
Toggle Summary Forward Pharma Appeals the Initial Decision in the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark , May 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of the notice of appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871
Toggle Summary Forward Pharma CEO to Present at the 42nd Annual Deutsche Bank Health Care Conference on May 4, 2017
COPENHAGEN, Denmark , May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen , the Company’s Chief Executive Officer, will present at the 42 nd Annual Deutsche Bank Health Care Conference , being held May 3-4, 2017 in Boston, MA.
Toggle Summary Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement
COPENHAGEN, Denmark , May 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”) today provided an update on the Company’s strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and License Agreement with
Toggle Summary Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results
COPENHAGEN, Denmark , April 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2016 . Net income for the fourth quarter December 31, 2016 was $9.6 million while net
Toggle Summary Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
COPENHAGEN, Denmark , March 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (“Forward Pharma” or the “Company”), a biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological
Toggle Summary Forward Pharma Appoints Claus Bo Svendsen as Chief Executive Officer and Plans to Reorganize to Reduce Burn Rate Following the Settlement and License Agreement with Biogen
COPENHAGEN, Denmark , March 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or the “Company”) today announced that its Board of Directors has appointed Claus Bo Svendsen , M.D., Ph.D. as Chief Executive Officer, effective March 1, 2017 .
Toggle Summary Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen
COPENHAGEN, Denmark , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that it has received a non-refundable cash fee of US$ 1.25 billion in connection with the execution and delivery of a Settlement and License Agreement with two wholly owned
Toggle Summary Forward Pharma Announces Results of Extraordinary General Meeting
Forward obtains shareholder approval for Settlement and License Agreement with Biogen COPENHAGEN, Denmark , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”) today announced that, at an extraordinary general meeting of its shareholders held on February 1, 2017
Toggle Summary Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen
Biogen will pay Forward a non-refundable cash fee of $1.25 billion Forward may be eligible to receive royalties of 10% of net sales of Tecfidera beginning in 2021, and of 20% of net sales beginning in 2029, depending on the outcome of certain existing litigation and the receipt of regulatory
Toggle Summary Forward Pharma Reports Third Quarter 2016 Financial and Operational Results
COPENHAGEN, Denmark , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the third quarter ended September 30, 2016 .  Net loss for the third quarter ended September 30, 2016 was $11.0 million , or $0.23 per
Toggle Summary Forward Pharma CFO to Participate in the Credit Suisse Annual Healthcare Conference in November
COPENHAGEN, Denmark , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek ,
Toggle Summary Forward Pharma CFO to Participate in Three Investor Conferences in September
COPENHAGEN, Denmark , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
Toggle Summary Forward Pharma Reports Second Quarter 2016 Financial and Operational Results
COPENHAGEN, Denmark , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward” or the “Company”), today reported financial results for the second quarter ended June 30, 2016 .  Net loss for the second quarter ended June 30, 2016 was $15.1 million , or $0.32 per basic
Toggle Summary Forward Pharma CFO to Participate in Two Investor Conferences in June
COPENHAGEN, Denmark , June 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
Toggle Summary Forward Pharma Reports First Quarter 2016 Financial and Operational Results
COPENHAGEN, Denmark , June 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the first quarter ended March 31, 2016 .  Net loss for the first quarter ended March 31, 2016 was $16.9 million , or $(0.36) per basic
Toggle Summary Forward Pharma Announces Board of Directors Expansion with Appointment of Two New Non-Executive Directors
COPENHAGEN, Denmark , May 09, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Karen Smith and Dr. Duncan Moore have been appointed to its Board of Directors as non-executive directors, expanding the Board to seven members.  Dr.
Toggle Summary Forward Pharma CFO to Present at the Deutsche Bank Health Care Conference
COPENHAGEN, Denmark , May 02, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
Toggle Summary Forward Pharma Reports Fourth Quarter and Year End 2015 Financial and Operational Results
COPENHAGEN, Denmark , April 12, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2015 . Net loss for the fourth quarter and year ended December 31, 2015 was $9.6 million
Toggle Summary Forward Pharma CFO to Participate in Two Investor Conferences in February
COPENHAGEN, Denmark, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S ( FWP ) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek,
Toggle Summary Forward Pharma Reports Third Quarter 2015 Financial and Operational Results
COPENHAGEN, Denmark , Nov. 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("We" or "Forward" or "Company"), today reported financial results for the third quarter ended September 30, 2015 . Net loss for the third quarter ended September 30, 2015 was $15.8 million , or $0.34 per share
Toggle Summary Forward Pharma Reports Second Quarter 2015 Financial and Operational Results
COPENHAGEN, Denmark , Sept. 8, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) ("We" or "Forward" or "Company"), today reported financial results for the second quarter ended June 30, 2015 . Net loss for the second quarter ended June 30, 2015 was $17.7 million , or $0.38 per share versus
Toggle Summary Forward Pharma CFO to Participate in Three Investor Conferences in September
COPENHAGEN, Denmark , Sept. 1, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel
Toggle Summary Forward Pharma CFO to Present at the JMP Securities Life Sciences Conference
COPENHAGEN, Denmark , June 19, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("Forward" or the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced
Toggle Summary Forward Pharma Reports First Quarter 2015 Financial and Operational Results
COPENHAGEN, Denmark , May 12, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("Forward" or the "Company"), today reported financial results for the first quarter ended March 31, 2015 . Net income for the first quarter ended March 31, 2015 was $5.3 million , or $0.11 per share.
Toggle Summary Forward Pharma CFO to Present at Two Investor Conferences in May
COPENHAGEN, Denmark , May 1, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company"), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek
Toggle Summary Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Covers the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R) COPENHAGEN, Denmark , April 27, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company") announced today that the Company received a decision to grant from the European
Toggle Summary U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Forward Receives Senior Party Status Based on Earlier Filing Date COPENHAGEN, Denmark , April 14, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company") announced today that an interference was declared by the Patent Trial and Appeal Board (PTAB) on April 13, 2015 between the
Toggle Summary Forward Pharma Pre-IPO Investors Voluntarily Agree to Extend Lock-Up
COPENHAGEN, Denmark , April 9, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) (the "Company" or "Forward") announced today an agreement among all of its pre-IPO shareholders to voluntarily lock-up their shares for an additional 365 days beyond the expiration of the original IPO lock-up.
Toggle Summary Forward Pharma Reports Fourth Quarter and Year End 2014 Financial and Operational Results
COPENHAGEN, Denmark , March 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), today reported financial results for the fourth quarter and year ended December 31, 2014 . Net loss for the fourth quarter and year ended December 31, 2014 was $2.0 million and $19.0 million , respectively.
Toggle Summary Forward Pharma CFO to Present at the Future Leaders Conference on March 20th
COPENHAGEN, Denmark , March 16, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel
Toggle Summary Forward Pharma CFO to Present at Two Upcoming Conferences in February
COPENHAGEN, Denmark , Feb. 5, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel
Toggle Summary Forward Pharma Receives Issue Notification for Erosion Matrix Patent in the U.S.
Covers Formulation of DMF, FP187, Into 2030 COPENHAGEN, Denmark , Nov. 24, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) ("the Company") announced today that the Company received an issue notification from the United States Patent and Trademark Office (USPTO) regarding its patent
Toggle Summary Forward Pharma Sues Biogen Idec Over Tecfidera(R) Sales in Germany
Alleges Infringement of Forward's German Utility Model COPENHAGEN, Denmark , Nov. 18, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP) announced today that it has filed a lawsuit against Biogen Idec GmbH , Biogen Idec International GmbH and Biogen Idec Ltd.
Toggle Summary Forward Pharma A/S Announces Closing of Partial Exercise of Over-Allotment Option
COPENHAGEN, Denmark , Nov. 14, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (the "Company") (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, announced
Toggle Summary Forward Pharma CFO to Present at Two Upcoming Conferences
COPENHAGEN, Denmark , Nov. 14, 2014 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq:FWP), a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, today announced that Joel
Toggle Summary Forward Pharma A/S Prices Initial Public Offering of ADSs
Toggle Summary Forward Pharma Announces Appointment of Dr. Jan G. J. van de Winkel to Board of Directors
Toggle Summary Joel Sendek joins Forward Pharma as Chief Financial Officer.
Toggle Summary Forward Pharma Files Registration Statement for IPO